Abstract
Coagulation dysfunction and thrombosis are major complications in patients with COVID-19. Patients on oral anticoagulants (OAC) prior to diagnosis of COVID-19 may therefore have better outcomes. In this multicentre observational study of 5883 patients (≥18 years) admitted to 26 UK hospitals between 1st of April to 31 July 2020, overall mortality was 29.2%. Incidences of thrombosis, major bleeding (MB) and multiorgan failure (MOF) were 5.4%,1.7% and 3.3% respectively. The presence of thrombosis, MB, or MOF were associated with a 1.8, 4.5 or 5.9-fold increased risk of dying, respectively.
Of the 5883 patients studied, 83.6% (n=4920) were not on OAC and 16.4% (n=963) were taking OAC at the time of admission. There was no difference in mortality between patients on OAC vs no OAC prior to admission when compared in an adjusted multivariate analysis (HR1.05(95%CI 0.93-1.19),P=0.15) or in an adjusted propensity score analysis (HR0.92(95%CI0.58-1.450, P=0.18). In multivariate and adjusted propensity score analyses, the only significant association of no anticoagulation prior to diagnosis of COVID-19 was admission to ICU (HR1.98[95%CI1.37-2.85]). Thrombosis, MB, and MOF were associated with higher mortality. Our results indicate that patients may have benefit from prior OAC use especially reduced admission to ICU, without any increase in bleeding.
Of the 5883 patients studied, 83.6% (n=4920) were not on OAC and 16.4% (n=963) were taking OAC at the time of admission. There was no difference in mortality between patients on OAC vs no OAC prior to admission when compared in an adjusted multivariate analysis (HR1.05(95%CI 0.93-1.19),P=0.15) or in an adjusted propensity score analysis (HR0.92(95%CI0.58-1.450, P=0.18). In multivariate and adjusted propensity score analyses, the only significant association of no anticoagulation prior to diagnosis of COVID-19 was admission to ICU (HR1.98[95%CI1.37-2.85]). Thrombosis, MB, and MOF were associated with higher mortality. Our results indicate that patients may have benefit from prior OAC use especially reduced admission to ICU, without any increase in bleeding.
Original language | English |
---|---|
Pages (from-to) | 79-94 |
Journal | British Journal of Haematology |
Volume | 196 |
Issue number | 1 |
Early online date | 9 Sept 2021 |
DOIs | |
Publication status | E-pub ahead of print - 9 Sept 2021 |
Keywords
- anticoagulation
- bleeding
- coronavirus disease 2019
- mortality
- thrombosis
ASJC Scopus subject areas
- Hematology